Relmada Therapeutics (RLMD) news
Recent news
Relmada Therapeutics appoints uro-oncology leader Bipin Dalmia as chief business officer
Relmada Therapeutics has announced the appointment of Bipin Dalmia as chief business officer, effective immediately. Dalmia brings extensive experience in uro-oncology and life sciences, having previously held [leadership roles at several biopharmaceutical companies][1]. In his new role, he will…
AInvest Wire · Jul 28, 2026Relmada Therapeutics, Inc.: H.C. Wainwright initiates coverage with buy rating
Relmada Therapeutics, Inc. (RLMD) has received a "Buy" rating from H.C. Wainwright, with the firm initiating coverage on the stock. The analyst, Robert Burns, cited the company’s chronic pain pipeline progress and ongoing development efforts as key factors in the recommendation. This aligns with…
AInvest Wire · Jun 18, 2026ImportantRelmada Therapeutics reports oversubscribed $160M placement financing
AInvest Wire · Mar 9, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.